In vitro

An in vivo CRS Evaluation Study in humanised mouse models can deliver fast, reproducible, and translatable data about drug safety in just two weeks. A humanised mouse platform offers the unique ability to preclinically analyse a fully systemic response that involves human immune cells and surrounding tissues. Furthermore, the platform also allows for efficacy testing […]

This paid-for advertorial by Manchester BioGel appeared in the DDW / ELRIG UK Drug Discovery 2021 supplement in DDW Volume 22, Issue 4 – Fall 2021   Communication of cells with their microenvironment is vital in understanding intracellular processes. Most matrices lack the mechanical and biochemical tuneability necessary to recreate the cancer microenvironment. Here we discuss how PeptiGels are able […]

An in vitro study of drugs already approved by the US Food and Drug Administration (FDA) to treat a range of conditions has shown eight of them are also effective in slowing SARS-CoV-2 replication in infected human cells. The team led by University of Manchester scientists used the drugs to treat liver and kidney cells, […]

This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing drug toxicity: new approaches and […]

UK-based Contract Research Organisation (CRO) Gentronix is set to expand its genetic toxicology capabilities and accelerate its growth following acquisition of the Big Blue transgenic mutation assay models. The acquisition ensures the continuing market provision of the Big Blue transgenic assays for companies requiring mutagenicity assessment under the OECD 488 guideline, with these studies playing […]

King’s College London is using CNBio’s PhysioMimix Multi-Organ MPS. Following a research collaboration, King’s College London selected the system to create a human-relevant liver-intestinal model for characterising and manipulating host-microbial interactions, to support improved outcomes in cirrhosis. Launched in March 20211, the product combines CN Bio’s in vitro 3D liver model with a range of […]

Avacta, developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has announced a licensing agreement with Biokit, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product. Biokit has experience in research, development and manufacturing of assays and biomaterial solutions for IVD use. Under the terms of the agreement […]

Eurofins Discovery is a CRO with a range of expertise in drug discovery. Christina Shasserre, Senior VP spoke to Lu Rahman about some of the company’s current COVID-related work as well as offering insight into the drug discovery landscape.   LR: Are you able to share some of Eurofins Discovery’s recent projects? CS: As we […]

BioIVT will be hosting a virtual Emerging Technologies in Diagnostics Symposium on  Thursday, October 29 (10am-1pm ET). “The diagnostic assay landscape is changing rapidly as the demand for faster, less expensive, more precise diagnostics continues to grow,” said Cathie Miller, Director of Product Marketing, Personalised Medicine at BioIVT. “We wanted to take this opportunity to […]